Share on StockTwits
 

Research analysts at Piper Jaffray set a $45.00 target price on shares of Insmed (NASDAQ:INSM) stock in a report released on Tuesday, Analyst Ratings Network reports. Piper Jaffray’s price objective indicates a potential upside of 170.92% from the stock’s current price.

Shares of Insmed (NASDAQ:INSM) opened at 16.61 on Tuesday. Insmed has a one year low of $5.85 and a one year high of $22.29. The stock’s 50-day moving average is $19.18 and its 200-day moving average is $15.65. The company’s market cap is $649.6 million.

INSM has been the subject of a number of other recent research reports. Analysts at UBS AG downgraded shares of Insmed from an “outperform” rating to an “underperform” rating in a research note on Tuesday, February 11th. They now have a $7.00 price target on the stock, down previously from $18.00. Separately, analysts at Wedbush downgraded shares of Insmed from an “outperform” rating to an “underperform” rating in a research note on Tuesday, February 11th. They now have a $7.00 price target on the stock, down previously from $18.00. Finally, analysts at JMP Securities upgraded shares of Insmed from a “market perform” rating to an “outperform” rating in a research note on Thursday, January 9th. They now have a $25.00 price target on the stock. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $22.17.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company specializing in recombinant protein drug development.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.